A clinically detailed guide to how toxic mold damages the peripheral and autonomic nervous systems — covering trichothecene neurotoxicity, ochratoxin A, small fiber neuropathy diagnosis, CIRS dysautonomia, and what recovery really looks like.
Peripheral neuropathy — nerve damage that causes numbness, tingling, burning pain, and weakness — has been documented in patients with significant mold exposure and mycotoxin illness. While the mainstream medical community has been slow to acknowledge mycotoxin-induced neuropathy, a growing body of research documents direct neurotoxic effects from several classes of mycotoxins produced by water-damaged building molds, including Stachybotrys chartarum, Aspergillus, Penicillium, and Fusarium species.
This guide covers the mechanisms of mycotoxin nerve damage, the specific toxins most implicated in neuropathy, how neuropathy presents in mold-illness patients versus other causes, and what diagnostic and treatment pathways are available.
The peripheral nervous system (PNS) consists of all the nerves outside the brain and spinal cord — sensory nerves that carry signals from skin, muscles, and organs to the brain, and motor nerves that carry signals from the brain to muscles. The autonomic nervous system (ANS), which controls involuntary functions like heart rate, blood pressure, digestion, and sweating, is also part of the PNS. Mycotoxins can attack each of these subsystems through multiple overlapping mechanisms.
Most large nerve fibers are covered by a myelin sheath — a fatty insulating layer that allows electrical signals to travel rapidly. Trichothecene mycotoxins produced by Stachybotrys and Fusarium species are potent inhibitors of protein synthesis, including the proteins that maintain and repair myelin. When myelin breaks down (demyelination), nerve conduction slows dramatically, producing sensations of numbness, heaviness, and diffuse tingling that can be difficult to localize.
In demyelinating neuropathies, nerve conduction velocity (NCV) studies will typically show slowed conduction speeds — a measurable, objective finding that clinicians can use to document nerve damage. The pattern in mycotoxin-exposed patients often resembles a multifocal or diffuse demyelinating polyneuropathy rather than the length-dependent stocking-and-glove pattern seen in diabetic neuropathy.
Beyond demyelination, certain mycotoxins cause axonal damage — direct destruction of the nerve fiber itself. Ochratoxin A (OTA), produced by Aspergillus ochraceus, Aspergillus niger, and several Penicillium species, binds to phenylalanine tRNA synthetase and blocks protein synthesis within neurons. OTA also generates reactive oxygen species (ROS) that cause oxidative stress in neuronal mitochondria, leading to energy failure and axonal die-back — the process where the nerve fiber degenerates from its distal end backward toward the cell body.
Axonal neuropathies present with more severe weakness and muscle wasting than pure demyelinating neuropathies, and they are slower to recover because the axon must physically regrow — a process that occurs at roughly 1 millimeter per day under optimal conditions.
In Chronic Inflammatory Response Syndrome (CIRS) — the systemic illness triggered by biotoxin exposure — peripheral neuropathy can also arise through immune-mediated neuroinflammation. Patients with certain HLA-DR/DQ genotypes (particularly those lacking the ability to clear biotoxins efficiently) develop sustained activation of the innate immune system. Elevated transforming growth factor beta-1 (TGF-beta-1) and matrix metalloproteinase-9 (MMP-9) levels, both markers of CIRS, have been associated with neuroinflammation that can affect peripheral nerve function.
In this pathway, the nerve damage is indirect — the immune system's inflammatory mediators, rather than the mycotoxins themselves, cause the neuropathy. This is relevant to treatment, because addressing the immune dysregulation (in addition to removing the biotoxin source) is essential for recovery.
Trichothecenes are a family of over 200 sesquiterpene mycotoxins, with the most clinically relevant being T-2 toxin, deoxynivalenol (DON), satratoxins (particularly satratoxin-G and satratoxin-H), and roridin A. Stachybotrys chartarum — the notorious black mold found in chronically water-damaged buildings — produces macrocyclic trichothecenes including the satratoxins and roridins, which are among the most potent inhibitors of eukaryotic protein synthesis known.
Animal studies — particularly those conducted by researchers at the University of Michigan — have demonstrated that intranasal exposure to satratoxin-G produces olfactory sensory neuron damage and neuroinflammation in the olfactory bulb. This is highly relevant to humans living in contaminated buildings, who inhale mycotoxin-laden spores and fragments through the nose continuously. The olfactory nerve (cranial nerve I) may be a primary entry point for mycotoxin-induced neurotoxicity, which could explain why loss of smell (anosmia) is frequently reported in mold-illness patients.
Once trichothecenes enter the systemic circulation — whether through inhalation, ingestion, or dermal absorption — they cross the blood-brain barrier and can affect central nervous system (CNS) neurons as well as peripheral nerves. T-2 toxin in particular has been shown to cause axonal degeneration in dorsal root ganglia neurons at concentrations achievable through environmental exposure.
Clinicians working with CIRS patients — including those following the Shoemaker Protocol — report a consistent constellation of peripheral symptoms in trichothecene-exposed patients:
These symptoms overlap with several other diagnoses, which is one reason mycotoxin-induced neuropathy is frequently missed or misattributed to other causes such as fibromyalgia or idiopathic small fiber neuropathy.
Ochratoxin A (OTA) is produced by multiple mold species commonly found in water-damaged buildings, including Aspergillus ochraceus, A. carbonarius, A. niger, and Penicillium verrucosum. Although OTA is best known for its nephrotoxic (kidney-damaging) effects, accumulating evidence points to significant neurological toxicity as well.
OTA's neurotoxic effects operate through at least three parallel pathways:
The autonomic nervous system is highly sensitive to OTA. Preclinical data shows that OTA disrupts norepinephrine synthesis and reuptake in sympathetic ganglia — the relay stations that control the fight-or-flight response and peripheral blood vessel tone. This may explain the dysautonomia symptoms frequently reported by mold-illness patients, including:
Postural Orthostatic Tachycardia Syndrome (POTS) — a condition in which heart rate increases by 30 or more beats per minute within 10 minutes of standing, causing dizziness, palpitations, and near-fainting — has been increasingly recognized in the CIRS patient population. The connection between biotoxin illness and POTS is multifactorial.
VIP is a neuropeptide that regulates blood vessel tone, particularly in the pulmonary circulation. In CIRS, VIP levels are frequently depressed — potentially because mycotoxin-driven inflammation downregulates VIP production in the hypothalamus. Low VIP impairs the body's ability to maintain appropriate vascular resistance during positional changes, contributing directly to orthostatic intolerance.
Dr. Ritchie Shoemaker's CIRS protocol includes VIP measurement as part of the neuroimmune panel, and VIP nasal spray has been used therapeutically to address both the pulmonary hypertension and dysautonomia components of advanced CIRS.
Alpha-melanocyte-stimulating hormone (alpha-MSH) — almost universally low in CIRS patients — plays a role in regulating the autonomic nervous system through its action on melanocortin receptors in the brainstem and hypothalamus. Low alpha-MSH is associated with disrupted circadian rhythms, abnormal temperature regulation, and disordered ANS responses. This explains the poor sleep quality, night sweats, and temperature dysregulation that accompany autonomic dysfunction in mold-illness patients.
Small fiber neuropathy (SFN) is a specific subtype of peripheral neuropathy affecting the thinly myelinated A-delta fibers and unmyelinated C fibers — the nerve fibers responsible for pain, temperature sensation, and autonomic functions. SFN is increasingly recognized as a component of CIRS and mold-related illness.
Critically, small fiber neuropathy does NOT show up on standard nerve conduction studies (NCS/EMG), which only measure large myelinated fiber function. This means that many mold-illness patients with genuine neuropathic symptoms will have normal NCS results, leading clinicians to dismiss their symptoms as psychosomatic. The proper diagnostic test for SFN is skin punch biopsy with intraepidermal nerve fiber density (IENFD) quantification — a test that directly counts the number of nerve endings per millimeter of skin and compares this to age- and sex-matched normative values.
| Mycotoxin | Source Mold | Primary Nerve Target | Neuropathy Pattern | Diagnostic Test | Recovery Outlook |
|---|---|---|---|---|---|
| Satratoxin-G/H | Stachybotrys chartarum | Olfactory neurons, dorsal root ganglia | Sensory polyneuropathy; anosmia; burning pain in extremities | Skin biopsy (IENFD); olfaction testing; trichothecene urine panel | Partial recovery 6–24 months post-exposure removal; anosmia may persist |
| Ochratoxin A (OTA) | Aspergillus ochraceus, A. niger, Penicillium verrucosum | Autonomic ganglia, peripheral sensory axons | Autonomic neuropathy; orthostatic intolerance; POTS; sensory axonopathy | OTA urine mycotoxin panel; tilt-table test; nerve biopsy | Good with early intervention and toxin elimination; autonomic recovery typically 12–18 months |
| T-2 Toxin | Fusarium sporotrichioides, F. poae | Dorsal root ganglia; peripheral motor and sensory fibers | Mixed sensorimotor neuropathy; proximal muscle weakness; fasciculations | NCS/EMG (may show axonal + demyelinating features); T-2 serum/urine testing | Variable; severe axonal damage recovers slowly (2–5 years); motor deficits may be permanent |
| Deoxynivalenol (DON) | Fusarium graminearum, F. culmorum | Central and peripheral nervous system; enteric nervous system | Neuroinflammatory neuropathy; gut dysmotility; cognitive neuropathy | DON urine panel; enterochromaffin cell markers; brain MRI (neuroinflammation) | Moderate; gut-brain axis symptoms improve with detox and diet; cognitive symptoms slow to clear |
| Aflatoxin B1 | Aspergillus flavus, A. parasiticus | Peripheral sensory fibers; hepatic nerve supply | Sensory neuropathy; paresthesias; neuropathic pain secondary to liver toxicity | Aflatoxin serum/urine panel; liver enzymes; NCS | Good if liver function preserved; neuropathy typically secondary and resolves with liver recovery |
| Gliotoxin | Aspergillus fumigatus | Schwann cells; immune nerve cells | Demyelinating neuropathy; immunosuppressive neuropathy in immunocompromised hosts | Aspergillus galactomannan; skin biopsy; NCS (slowed velocity) | Dependent on immune status; immunocompetent patients recover more completely |
| Citrinin | Penicillium citrinum, Monascus spp. | Peripheral autonomic fibers; renal nerve supply | Autonomic dysfunction secondary to nephrotoxicity; reduced heart rate variability | Citrinin urine panel; HRV analysis; renal function testing | Improves with nephrotoxicity management; usually full autonomic recovery if kidneys preserved |
For a broader overview of how mycotoxins affect overall health, see our Toxic Mold Syndrome Guide and our Black Mold Health Effects Guide.
One of the most frustrating aspects of mycotoxin-induced neuropathy is that standard neurological workups frequently come back normal, leading patients to be told their symptoms are functional or psychosomatic. This is not because the neuropathy isn't real — it's because the standard tests are not sensitive to the types of neuropathy that mycotoxins cause. Here is a complete guide to the diagnostic tests that are relevant in suspected mold-related neuropathy:
NCS measures how quickly electrical signals travel along specific nerves and how large those signals are. EMG measures the electrical activity of muscles at rest and during contraction. Together, NCS/EMG can distinguish demyelinating neuropathy (slowed conduction velocity, prolonged distal latencies), axonal neuropathy (reduced amplitude of nerve signals), and neuromuscular junction disorders. NCS/EMG will be normal in pure small fiber neuropathy. A normal NCS/EMG does not rule out neuropathy — it only rules out large fiber neuropathy.
This is the gold-standard test for small fiber neuropathy. A 3-mm punch biopsy is taken from the distal leg (lateral calf, 10 cm above the lateral malleolus) and sometimes also from the proximal thigh. The biopsy is stained with protein gene product 9.5 (PGP 9.5) antibody, which labels all nerve fibers in the epidermis, and the nerve fiber density is quantified under confocal microscopy.
Reduced IENFD (below the 5th percentile for age- and sex-matched norms) confirms small fiber neuropathy. This test requires a specialized neuropathology laboratory. Major medical centers with neurology departments, and reference labs such as Therapath Neuropathology in New York, perform this analysis reliably.
The autonomic nervous system can be evaluated through several non-invasive tests:
Mycotoxin urine testing, offered by labs such as RealTime Laboratories and Vibrant America, allows direct measurement of mycotoxin metabolites in urine. While these tests are not yet FDA-cleared for diagnostic purposes and have significant methodological variability between laboratories, they can provide supportive evidence of ongoing mycotoxin exposure, particularly when combined with environmental testing of the building.
See our Comprehensive Mold Testing Guide for details on environmental mycotoxin sampling methods.
If CIRS is suspected as the underlying mechanism of neuropathy, the following biomarkers are relevant:
Not every case of peripheral neuropathy is related to mold exposure. The most common causes in the general population are diabetes mellitus, alcohol use disorder, vitamin B12 deficiency, thyroid disease, and hereditary conditions. However, several clinical features should raise suspicion for mycotoxin-induced neuropathy specifically:
Related neurological symptoms worth exploring include our guides on mold-related vertigo and balance problems, mold-triggered depression and mood disorders, and mold and chronic fatigue syndrome.
Recovery from mycotoxin-induced peripheral neuropathy requires a multi-pronged approach. The single most important intervention is removing the source of exposure — leaving the contaminated building and, if possible, leaving behind contaminated belongings that may harbor mycotoxins. No treatment will work if ongoing exposure continues.
Once out of the contaminated environment, the body begins to eliminate mycotoxins, but this process requires support:
Once the toxin burden is being addressed, neuropathy-specific treatments can be layered in:
Dysautonomia and POTS require specific management beyond toxin elimination:
Mycotoxin-induced neuropathy can improve substantially — but it requires patience, a thorough elimination of exposure, and a systematic treatment approach. Patients who leave the contaminated environment promptly and pursue comprehensive treatment have the best outcomes. Patients who remain in contaminated buildings — even part-time — will not recover, because ongoing exposure continuously reloads the toxin burden.
For an overview of what comprehensive mold remediation involves, see our Mold Remediation Process Guide and our Mold Inspection Guide.
Peripheral neuropathy rarely occurs in isolation in mold-illness patients. The systemic nature of mycotoxin exposure means that multiple organ systems are typically affected simultaneously. Understanding the co-occurring conditions helps explain why mold patients are often dismissed — their symptom pattern crosses multiple specialties, and no single specialist sees the whole picture.
Common co-occurring conditions with mycotoxin neuropathy include:
Not all physicians are trained in diagnosing or treating mycotoxin-induced neuropathy. When seeking medical care, look for providers who:
The Institute for Functional Medicine (IFM), the American Academy of Environmental Medicine (AAEM), and the Surviving Mold physician directory at survivingmold.com maintain lists of practitioners familiar with biotoxin illness.
At the same time, the most critical action you can take is eliminating the mold source in your home or workplace. Professional mold inspection and remediation is the foundation on which all other treatments depend.
Yes. Multiple mycotoxins produced by water-damaged building molds have demonstrated neurotoxic effects in both animal models and clinical populations. Trichothecenes, ochratoxin A, and gliotoxin are particularly implicated. The neuropathy most commonly manifests as small fiber neuropathy (affecting pain and temperature fibers) and autonomic neuropathy (affecting the involuntary nervous system), both of which can be missed on standard nerve conduction studies.
For most patients, yes — provided the exposure is eliminated completely and appropriate supportive treatment is initiated. Small fiber neuropathy has demonstrated capacity to recover (regrowth of intraepidermal nerve fibers) once the toxic insult is removed. The critical variables are the duration of exposure before removal, the severity of the neuropathy at baseline, and whether the patient receives appropriate mycotoxin-elimination support.
Diabetic neuropathy typically presents in a length-dependent pattern — worst in the feet, gradually ascending the legs — and is associated with documented hyperglycemia. Mycotoxin neuropathy more often presents in a non-length-dependent or multifocal pattern, affects the autonomic nervous system prominently (POTS, sweating abnormalities), and occurs in the context of multi-system illness including cognitive symptoms, fatigue, and immune dysregulation.
A combination approach is most effective: skin punch biopsy for IENFD quantification (gold standard for small fiber neuropathy), autonomic testing (tilt-table, QSART), mycotoxin urine panel, and CIRS biomarker panel. See our Mold Testing Guide for information on environmental testing to confirm your exposure source.
Costs vary significantly by the extent of contamination and the surfaces affected. Our Mold Removal Cost Guide provides detailed breakdowns by remediation type, and our Mold Remediation Process Guide explains what a thorough remediation involves.